Besides TB, several strategies are being tested as possible prognostic and predictive factors of recurrence in stage II CRC, precisely to help the decision of the adjuvant chemotherapy in this setting [37, 38], such as gene platforms, molecular evaluations of circulating tumour DNA, immunohistochemistry expression of CDX2 and immunoscore, among others. This evidence concerns the gene CDX2 and neoplasm.